Collegium Medicum, Jagiellonian University, Cracow, Poland.
Ginekol Pol. 2022;93(6):489-495. doi: 10.5603/GP.a2021.0192. Epub 2022 Jan 24.
Local and international organizations recommend folic acid (FA) supplementation in the periconceptional period. This study aimed to analyse the prevalence of periconceptional supplementation with FA in women at high risk of fetal anomalies refferred for first trimester screening.
Our analysis involved 1,455 women at high risk of fetal anomalies refferred for first trimester screening. FA supplementation was assessed by face-to-face interviews conducted by doctors performing first trimester screening for aneuploidy.
FA supplementation before pregnancy was reported by 46.8% of the women and during the first trimester by 57.2% of those studied. Women used FA supplementation more frequently if they had a history of at least one miscarriage (OR 2.2, 95% CI 1.70-2.83; p < 0.001), a history of assissted reproductive techniques (OR 2.25, 95% CI 1.18-4.31; p = 0.014), or were aged between 30 and 34 (OR 2.87, 95% CI 1.47-5.58; p = 0.002). Among 122 women with a history of fetal defects only 50% confirmed FA supplementation before pregnancy and 62.2% during pregnancy (p = 0.488). A similar frequency of FA supplementation was noted among women with epilepsy, diabetes, and hypertension. Less frequent taking of FA was noted among women at least third and subsequent pregnancies (p < 0.001). In the current pregnancy, neural tube defects (NTDs) were less frequent by 86% in the group of women with FA supplementation than in the non-supplementation group (1 case vs 6 cases, respectively) and for other fetal defects by 62.5% (24 vs 40 cases, respectively).
We found an unsatisfactory compliance with recommendations for the use of folic acid supplementation during periconceptional period among women at high risk of fetal defects and folate deficiency, that could have negative effects on the health of child and mother. The study results show the need to increase the awareness of FA supplementation during periconceptional period especially in women with high risk of fetal anomalies.
当地和国际组织建议在围孕期补充叶酸(FA)。本研究旨在分析在因胎儿畸形高风险而接受早孕期筛查的女性中,围孕期补充 FA 的流行情况。
我们的分析纳入了 1455 名因胎儿畸形高风险而接受早孕期筛查的女性。通过进行早孕期非整倍体筛查的医生进行面对面访谈,评估 FA 补充情况。
46.8%的女性报告在怀孕前补充 FA,57.2%的女性在研究期间补充 FA。如果女性有至少一次流产史(OR 2.2,95%CI 1.70-2.83;p<0.001)、辅助生殖技术史(OR 2.25,95%CI 1.18-4.31;p=0.014)或年龄在 30-34 岁之间(OR 2.87,95%CI 1.47-5.58;p=0.002),则更频繁地使用 FA 补充剂。在 122 名有胎儿缺陷史的女性中,只有 50%确认在怀孕前补充 FA,62.2%在怀孕期间补充(p=0.488)。在患有癫痫、糖尿病和高血压的女性中,FA 补充剂的使用频率相似。在至少第三次及以后妊娠的女性中,FA 的服用频率较低(p<0.001)。在当前妊娠中,与未补充组相比,补充 FA 的女性神经管缺陷(NTD)的发生率降低了 86%(1 例与 6 例,分别),其他胎儿缺陷的发生率降低了 62.5%(24 例与 40 例,分别)。
我们发现,在因胎儿畸形和叶酸缺乏高风险而接受早孕期筛查的女性中,围孕期补充 FA 的依从性不理想,这可能对母婴健康产生负面影响。研究结果表明,需要提高女性对围孕期补充 FA 的认识,尤其是对有胎儿畸形高风险的女性。